Search

Garetosmab

Garetosmab-grts is an activin A inhibitor used to treat fibrodysplasia ossificans progressiva (FOP). … [L63940] It is a fully human IgG4 monoclonal antibody that binds and neutralizes activin A, blocking activin A from activating the mutant ACVR1 receptor that, in FOP, drives the formation of heterotopic

Florilglutamic acid F-18

Florilglutamic acid F-18 is under investigation in clinical trial NCT02370563 (PET Imaging of Intracranial Cancers With 18F-FSPG).

Rolapitant

Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and … Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.

Difamilast

[L56052, A275420] This skin disease occurs most frequently in children and can have an onset as early as within the first 2 years of life. … [L55042, A275424, A275420] As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production

Nafamostat

The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury. … Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties.

Cinnamyl alcohol

Due to the low levels found in cinnamon, cinnamyl alcohol is usually supplied as [DB14184] within commercial products. … Cinnamyl alcohol has been shown to be a skin sensitizer, with a NOEL (No Effect Level) of ~4% [A34266]. Sensitivity to cinnamyl alcohol may be identified with a clinical patch test.

Minigastrin

Minigastrin is under investigation in clinical trial NCT06155994 (68ga-dota-mgs5 PET/CT in Patients With Advanced Neuroendocrine Tumours).

DP-VPA

DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure

Dexrazoxane

An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. … [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.

Cariporide